Sanavia Oncology

1 known investors

Sanavia develops cancer therapies—including antibody drug conjugates (ADCs), bispecific T cell engagers, and CAR-T cell therapies—that target novel epitopes in validated cancer targets. It uses an immunology-driven AI and machine learning platform to accelerate early-stage drug discovery for biotech partners and patients.